{
    "2018-02-09": [
        [
            {
                "time": "2018-02-01",
                "original_text": "Novartis Faces Investigation For Alleged Bribery In Greece",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Investigation",
                        "Alleged Bribery",
                        "Greece"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "What’s Expected of Novartis’s Core Operating Income in 2018?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Core Operating Income",
                        "2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "Why Novartis Is Expected to Report Modest Revenue Growth in 2018",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Modest Revenue Growth",
                        "2018"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "Novartis and Peers in February 2018: Analyst Recommendations",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Peers",
                        "Analyst Recommendations",
                        "February 2018"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "The Zacks Analyst Blog Highlights: Novartis, BP and Biogen",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Novartis",
                        "BP",
                        "Biogen"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "energy",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "Analyst: Regeneron Is Undervalued By The Street",
                "features": {
                    "keywords": [
                        "Regeneron",
                        "Undervalued",
                        "Street"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "A Look at Amgen’s Nplate, Vectibix, and Neupogen in 4Q17",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Nplate",
                        "Vectibix",
                        "Neupogen",
                        "4Q17"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "Why Sanofi Has Received a Negative Outlook from Fitch Ratings",
                "features": {
                    "keywords": [
                        "Sanofi",
                        "Negative Outlook",
                        "Fitch Ratings"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "Will Teva Pharmaceutical's Pain Be Mylan's Gain?",
                "features": {
                    "keywords": [
                        "Teva Pharmaceutical",
                        "Mylan",
                        "Pain",
                        "Gain"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "How the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy",
                "features": {
                    "keywords": [
                        "Ablynx",
                        "Acquisition",
                        "Sanofi",
                        "R&D Strategy"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "How Amgen’s Xgeva and Prolia Performed in 4Q17",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Xgeva",
                        "Prolia",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform",
                "features": {
                    "keywords": [
                        "Ablynx",
                        "Acquisition",
                        "SNY",
                        "Rare Blood Disorder"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "The Swiss Stock Market Ends Another Turbulent Session In The Red",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Turbulent Session",
                        "Red"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}